Compare SMWB & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMWB | ARMP |
|---|---|---|
| Founded | 2007 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.5M | 295.5M |
| IPO Year | 2021 | 1996 |
| Metric | SMWB | ARMP |
|---|---|---|
| Price | $4.39 | $7.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $4.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 928.6K | 63.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.07 | N/A |
| Revenue Next Year | $11.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.22 | $1.74 |
| 52 Week High | $10.75 | $14.98 |
| Indicator | SMWB | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 71.46 | 41.35 |
| Support Level | $2.44 | $7.22 |
| Resistance Level | $7.82 | $7.93 |
| Average True Range (ATR) | 0.32 | 0.81 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 83.91 | 43.72 |
Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.